Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis

S. Ravaglia, C. Danesino, A. Moglia, A. Costa, H. Cena, L. MacCarini, A. Carlucci, A. Pichiecchio, P. Bini, P. De Filippi, M. Rossi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: In adult glycogen storage disease type II (GSDII), a single-gene mutation causes reduction of the lysosomal enzyme acid alpha-glucosidse. This produces a chronic proximal myopathy with respiratory involvement. Enzyme replacement treatment (ERT) has recently become available and is expected to improve muscle strength. This should result in increased lean body mass. In this study we evaluate body composition and nutritional status in GSDII, and assess whether these parameters changed during treatment. Methods: Seventeen patients with late-onset GSDII, aged 52.6 ± 16.8 years, received ERT for >18 months. Dietary habits and metabolic profiles of glucids, lipids, and proteins were assessed. Body composition was calculated using anthropometry and bioelectrical impedence analysis. Results: On inclusion, we found increased fat mass (FM) in five patients in severe disease stage; all had normal body mass index (BMI). FM correlated inversely, and lean mass (LM) directly, with creatine kinase, prealbumin and albumin levels. After treatment, BMI and FM significantly increased, while LM only showed a trend toward increase. Prealbumin and albumin levels increased as early as after the first months of ERT. Discussion: Body mass index value may underestimate FM in patients in severe stage of disease, due to altered body composition. In severely affected patients, laboratory parameters revealed a relative protein malnutrition, that was reversed by ERT, this reflecting restoration of normal muscle metabolic pathways. Increased BMI may indicate a reduction in energy consumption during exercise or respiration, along with clinical improvement.

Original languageEnglish
Pages (from-to)957-962
Number of pages6
JournalEuropean Journal of Neurology
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Body Composition
Nutritional Status
Body Mass Index
Fats
Enzymes
Prealbumin
Albumins
Therapeutics
Anthropometry
Metabolome
Muscle Strength
Feeding Behavior
Muscular Diseases
Creatine Kinase
Metabolic Networks and Pathways
Malnutrition
Respiration
Proteins

Keywords

  • anthropometric measures
  • body composition
  • enzyme replacement therapy
  • myozyme
  • Pompe disease
  • type II glycogenosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. / Ravaglia, S.; Danesino, C.; Moglia, A.; Costa, A.; Cena, H.; MacCarini, L.; Carlucci, A.; Pichiecchio, A.; Bini, P.; De Filippi, P.; Rossi, M.

In: European Journal of Neurology, Vol. 17, No. 7, 07.2010, p. 957-962.

Research output: Contribution to journalArticle

@article{823072df141c4233b0395587296ccc56,
title = "Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis",
abstract = "Background: In adult glycogen storage disease type II (GSDII), a single-gene mutation causes reduction of the lysosomal enzyme acid alpha-glucosidse. This produces a chronic proximal myopathy with respiratory involvement. Enzyme replacement treatment (ERT) has recently become available and is expected to improve muscle strength. This should result in increased lean body mass. In this study we evaluate body composition and nutritional status in GSDII, and assess whether these parameters changed during treatment. Methods: Seventeen patients with late-onset GSDII, aged 52.6 ± 16.8 years, received ERT for >18 months. Dietary habits and metabolic profiles of glucids, lipids, and proteins were assessed. Body composition was calculated using anthropometry and bioelectrical impedence analysis. Results: On inclusion, we found increased fat mass (FM) in five patients in severe disease stage; all had normal body mass index (BMI). FM correlated inversely, and lean mass (LM) directly, with creatine kinase, prealbumin and albumin levels. After treatment, BMI and FM significantly increased, while LM only showed a trend toward increase. Prealbumin and albumin levels increased as early as after the first months of ERT. Discussion: Body mass index value may underestimate FM in patients in severe stage of disease, due to altered body composition. In severely affected patients, laboratory parameters revealed a relative protein malnutrition, that was reversed by ERT, this reflecting restoration of normal muscle metabolic pathways. Increased BMI may indicate a reduction in energy consumption during exercise or respiration, along with clinical improvement.",
keywords = "anthropometric measures, body composition, enzyme replacement therapy, myozyme, Pompe disease, type II glycogenosis",
author = "S. Ravaglia and C. Danesino and A. Moglia and A. Costa and H. Cena and L. MacCarini and A. Carlucci and A. Pichiecchio and P. Bini and {De Filippi}, P. and M. Rossi",
year = "2010",
month = "7",
doi = "10.1111/j.1468-1331.2010.02959.x",
language = "English",
volume = "17",
pages = "957--962",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis

AU - Ravaglia, S.

AU - Danesino, C.

AU - Moglia, A.

AU - Costa, A.

AU - Cena, H.

AU - MacCarini, L.

AU - Carlucci, A.

AU - Pichiecchio, A.

AU - Bini, P.

AU - De Filippi, P.

AU - Rossi, M.

PY - 2010/7

Y1 - 2010/7

N2 - Background: In adult glycogen storage disease type II (GSDII), a single-gene mutation causes reduction of the lysosomal enzyme acid alpha-glucosidse. This produces a chronic proximal myopathy with respiratory involvement. Enzyme replacement treatment (ERT) has recently become available and is expected to improve muscle strength. This should result in increased lean body mass. In this study we evaluate body composition and nutritional status in GSDII, and assess whether these parameters changed during treatment. Methods: Seventeen patients with late-onset GSDII, aged 52.6 ± 16.8 years, received ERT for >18 months. Dietary habits and metabolic profiles of glucids, lipids, and proteins were assessed. Body composition was calculated using anthropometry and bioelectrical impedence analysis. Results: On inclusion, we found increased fat mass (FM) in five patients in severe disease stage; all had normal body mass index (BMI). FM correlated inversely, and lean mass (LM) directly, with creatine kinase, prealbumin and albumin levels. After treatment, BMI and FM significantly increased, while LM only showed a trend toward increase. Prealbumin and albumin levels increased as early as after the first months of ERT. Discussion: Body mass index value may underestimate FM in patients in severe stage of disease, due to altered body composition. In severely affected patients, laboratory parameters revealed a relative protein malnutrition, that was reversed by ERT, this reflecting restoration of normal muscle metabolic pathways. Increased BMI may indicate a reduction in energy consumption during exercise or respiration, along with clinical improvement.

AB - Background: In adult glycogen storage disease type II (GSDII), a single-gene mutation causes reduction of the lysosomal enzyme acid alpha-glucosidse. This produces a chronic proximal myopathy with respiratory involvement. Enzyme replacement treatment (ERT) has recently become available and is expected to improve muscle strength. This should result in increased lean body mass. In this study we evaluate body composition and nutritional status in GSDII, and assess whether these parameters changed during treatment. Methods: Seventeen patients with late-onset GSDII, aged 52.6 ± 16.8 years, received ERT for >18 months. Dietary habits and metabolic profiles of glucids, lipids, and proteins were assessed. Body composition was calculated using anthropometry and bioelectrical impedence analysis. Results: On inclusion, we found increased fat mass (FM) in five patients in severe disease stage; all had normal body mass index (BMI). FM correlated inversely, and lean mass (LM) directly, with creatine kinase, prealbumin and albumin levels. After treatment, BMI and FM significantly increased, while LM only showed a trend toward increase. Prealbumin and albumin levels increased as early as after the first months of ERT. Discussion: Body mass index value may underestimate FM in patients in severe stage of disease, due to altered body composition. In severely affected patients, laboratory parameters revealed a relative protein malnutrition, that was reversed by ERT, this reflecting restoration of normal muscle metabolic pathways. Increased BMI may indicate a reduction in energy consumption during exercise or respiration, along with clinical improvement.

KW - anthropometric measures

KW - body composition

KW - enzyme replacement therapy

KW - myozyme

KW - Pompe disease

KW - type II glycogenosis

UR - http://www.scopus.com/inward/record.url?scp=77953831502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953831502&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2010.02959.x

DO - 10.1111/j.1468-1331.2010.02959.x

M3 - Article

C2 - 20158513

AN - SCOPUS:77953831502

VL - 17

SP - 957

EP - 962

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 7

ER -